Bromide

Bromide

SCHEMBL1731971

Br.CCOc1cc2c(c(F)c1OCC)C(=N)N(CC(=O)c1ccc3c(c1)C(C)(C)C(C)N3C)C2

nearest known ligand 0.54

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4

The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
F2R P25116 6/20 0.54
MAPT P10636 2/20 0.34
THRB P10828 2/20 0.34
MEN1 O00255 1/20 0.34
KDM4A O75164 1/20 0.34
POLB P06746 1/20 0.34
RECQL P46063 1/20 0.34
KMT2A Q03164 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
KDM4E B2RXH2 1/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
TP53 P04637 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1729623 0.99 F2R (0.52) F2RMAPTTHRBMEN1KDM4A
Bromide SCHEMBL5484925 0.90 F2R (0.51) F2RMAPTKDM4ENPC1RAB9A
Bromide SCHEMBL1730981 0.88 F2R (0.49) F2RMAPTKDM4ENPC1RAB9A
Bromide SCHEMBL1732128 0.87 F2R (0.54) F2RMAPTTHRBSMN1; SMN2KDM4E
Bromide SCHEMBL1730041 0.86 F2R (0.52) F2RMAPTTHRBMEN1KMT2A
Bromide SCHEMBL5484900 0.84 F2R (0.51) F2RMAPTTHRBKDM4ENPC1
Bromide SCHEMBL1730216 0.84 F2R (0.49) F2RMAPTKDM4ENPC1RAB9A
SCHEMBL27527338 0.83 F2R (0.41) F2RMAPTTHRBMEN1KDM4A
Bromide SCHEMBL1729488 0.82 F2R (0.52) F2RMAPTSMN1; SMN2KDM4ENPC1
Bromide SCHEMBL1731506 0.82 F2R (0.53) F2RMAPTTHRBKDM4ENPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1391451-B1 2-IMINOPYRROLIDINE DERIVATES EISAI R&D MAN CO LTD (JP) 2011-11-23 EP disclosed
US-7244730-B2 2-iminopyrrolidine derivatives EISAI CO., LTD (JP) 2007-07-17 US disclosed
US-20050245592-A1 2-Iminopyrrolidine derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2005-11-03 US disclosed
US-20050004204-A1 2-Iminopyrrolidine derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2005-01-06 US disclosed
EP-1391451-A1 2-IMINOPYRROLIDINE DERIVATES Eisai Co., Ltd. (JP) 2004-02-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050245592-A1 2-Iminopyrrolidine derivatives H1-2, H1-3, H1-0 F2R 2290/4885MAPT 3483/4885THRB 2315/4885
US-20050004204-A1 2-Iminopyrrolidine derivatives H1-2, H1-3, H1-0 F2R 2289/4885MAPT 3440/4885THRB 2297/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.